Drugs Made In America Acquisition Corp
DMAA
18 hedge funds and large institutions have $103M invested in Drugs Made In America Acquisition Corp in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27.26% less ownership
Funds ownership: 68.23% → 40.98% (-27%)
54% less funds holding
Funds holding: 39 → 18 (-21)
56% less capital invested
Capital invested by funds: $237M → $103M (-$134M)
75% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 12
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$737K |
| 2 |
CS
Clear Street
New York
|
+$301K |
| 3 |
JP Morgan Chase
New York
|
+$106 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$15.4M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$11.5M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$7.64M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.25M |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$5.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LGM
26
L1 Global Manager
Melbourne,
| – | -$2.1M | -200,000 | Closed |
|
27
Goldman Sachs
New York
| – | -$1.25M | -119,686 | Closed |
|
|
DAM
28
DLD Asset Management
New York
| – | -$1.05M | -100,559 | Closed |
|
|
WAM
29
Warberg Asset Management
Winnetka,
Illinois
| – | -$966K | -92,054 | Closed |
|
|
PC
30
Periscope Capital
Toronto,
Ontario, Canada
| – | -$525K | -50,000 | Closed |
|
31
BNP Paribas Financial Markets
Paris,
France
| – | -$154K | -14,737 | Closed |
|
32
Citadel Advisors
Miami,
Florida
| – | -$110K | -10,476 | Closed |
|
DMAA Hedge Fund Activity: Q2 2026 in Review
18 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q2 2026, worth a combined $103M — down 56% from $237M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DMAA and 0 opened new positions — a net loss of 14 holders — while 12 trimmed existing stakes and 3 added.
The largest buyer was Mizuho Securities USA, adding an estimated $737K. The largest seller was First Trust Capital Management, cutting an estimated $15.4M.
- 18 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q2 2026, down from 39 in Q1 2026.
- Funds reported $103M of Drugs Made In America Acquisition Corp stock for Q2 2026, down 56% quarter-over-quarter.
- 0 funds opened new Drugs Made In America Acquisition Corp positions in Q2 2026 and 14 closed out, a net change of -14 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q2 2026 was Mizuho Securities USA, an estimated $737K added.
- The largest Drugs Made In America Acquisition Corp seller in Q2 2026 was First Trust Capital Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2026.